Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 4:38 AM ET

Biotechnology

Company Overview of Affimed N.V.

Company Overview

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company’s product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor v...

Technologiepark

Im Neuenheimer Feld 582

Heidelberg,  69120

Germany

Founded in 2000

52 Employees

Phone:

49 6221 65307 0

Fax:

49 6221 65307 77

Key Executives for Affimed N.V.

Chief Executive Officer and Member of Management Board
Age: 52
Total Annual Compensation: $297.0K
Chief Financial Officer and Member of Management Board
Age: 46
Total Annual Compensation: $190.0K
Chief Medical Officer and Member of Management Board
Age: 51
Total Annual Compensation: $352.0K
Compensation as of Fiscal Year 2014.

Affimed N.V. Key Developments

Affimed Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Affimed reported unaudited Consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net loss was EUR 5.3 million, or EUR 0.22 per common share, compared to a net loss of EUR 2.6 million, or EUR 0.17 per common share for fourth quarter of 2013. The company reported revenue of EUR 81,000 compared to EUR4.6 million for fourth quarter of 2013 due to milestone achievement-related revenue recognition under the Amphivena collaboration in the 2013 period. Loss before tax was EUR 5,428,000 against EUR 2,542,000 a year ago. Net cash used in operating activities was EUR 5,444,000 against EUR 2,268,000 a year ago. Purchase of intangible assets was EUR 10,000 against EUR 5,000 a year ago. Purchase of leasehold improvements and equipment was EUR 18,000 against EUR 11,000 a year ago. Net loss for the full year 2014 was EUR 0.3 million or EUR 0.01 per common share, compared to a loss of EUR 26.1 million or EUR 1.76 per common share for the full year 2013. The decrease is primarily related to a credit to the share-based payment expense resulting from a re-measurement gain at consummation of the IPO. Loss before tax was EUR 425,000 against EUR 26,100,000 a year ago. Net cash used in operating activities was EUR 10,547,000 against EUR 5,678,000 a year ago. Purchase of intangible assets was EUR 45,000 against EUR 23,000 a year ago. Purchase of leasehold improvements and equipment was EUR 260,000 against EUR 139,000 a year ago. Revenue was EUR 3,382,000 against EUR 5,087,000 a year ago. Operating loss was EUR 8,178,000 against EUR 15,703,000 a year ago. The increase in net cash used in operating activities was primarily related to the increase in cash based expenses for research and development (R&D) in connection with development and collaboration programs and general and administrative expenses in relation to the preparation for the IPO and other financing transactions.

Affimed N.V. Presents at BioCapital Europe 2015, Mar-26-2015 02:40 PM

Affimed N.V. Presents at BioCapital Europe 2015, Mar-26-2015 02:40 PM. Venue: Sofitel Legend Amsterdam, Amsterdam, Netherlands.

Affimed N.V. to Report Q4, 2014 Results on Mar 25, 2015

Affimed N.V. announced that they will report Q4, 2014 results on Mar 25, 2015

Similar Private Companies By Industry

Company Name Region
Pharmacelsus GmbH Europe
t-cell Europe GmbH Europe
Institute of Plant Biochemistry Europe
Sloning BioTechnology GmbH Europe
PomBio Tech GmbH Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 2, 2014
--
Private Placement
June 24, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Affimed N.V., please visit www.affimed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.